Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
1.435
-0.155 (-9.75%)
Mar 31, 2025, 1:15 PM EDT - Market open
Precigen Revenue
In the year 2024, Precigen had annual revenue of $3.93M, down -36.95%. Precigen had revenue of $1.19M in the quarter ending December 31, 2024, a decrease of -3.09%.
Revenue (ttm)
$3.93M
Revenue Growth
-36.95%
P/S Ratio
108.46
Revenue / Employee
$27,448
Employees
143
Market Cap
421.95M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.93M | -2.30M | -36.95% |
Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
Dec 31, 2021 | 14.27M | -17.73M | -55.40% |
Dec 31, 2020 | 31.99M | -58.73M | -64.74% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PGEN News
- 11 days ago - Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Precigen Reports Full Year 2024 Financial Results and Business Updates - PRNewsWire
- 18 days ago - Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th - PRNewsWire
- 4 weeks ago - Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement - Seeking Alpha
- 4 weeks ago - FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 - PRNewsWire
- 2 months ago - Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 3 months ago - Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis - PRNewsWire